Remdesivir, an intravenous nucleotide prodrug, has been approved for treating COVID-19 in
hospitalized adults and pediatric patients. Upon administration, remdesivir can be readily …

Abstract Remdesivir (RDV, Veklury®) is an FDA-approved prodrug for the treatment of
hospitalized patients with COVID-19. Recent in vitro studies have indicated that human …

Remdesivir was recently approved to treat COVID‐19. While this antiviral agent delivers
clinical benefits, several safety concerns in many cases have been raised. This study reports …

ABSTRACT Remdesivir (RDV; GS-5734, Veklury), the first FDA-approved antiviral to treat
COVID-19, is a single-diastereomer monophosphoramidate prodrug of an adenosine …

Background Remdesivir has received significant attention for its potential application in the
treatment of COVID-19, caused by SARS-CoV-2. Remdesivir has already been tested for …

The expanding epidemic of coronavirus disease 2019 (COVID-19), caused by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a serious threat to the …

Remdesivir (RDV), a nucleoside analogue prodrug, is used to treat viral diseases including
COVID-19. The drug (RDV) was stressed under acidic, basic and neutral hydrolysis …

Background: Remdesivir has received significant attention for its potential application in the
treatment of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS …

The nucleotide analogue prodrug remdesivir remains the only FDA-approved antiviral small
molecule for the treatment of infection with SARS-CoV-2. Biochemical studies revealed that …

On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus
Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems …